SHANGHAI, Oct. 29, 2026 /PRNewswire/ — United Imaging Healthcare (688271.SH), a global innovator in advanced medical imaging technologies and intelligent healthcare solutions, announced its financial results for the first nine months of 2026, reporting revenue of RMB 10.58 billion, up 19.43% year-on-year. In the third quarter, revenue reached RMB 3.53 billion, while net profit attributable to shareholders rose 13% year-on-year to RMB 138 million.
International business continued to be a key growth driver. Revenue from international markets reached RMB 3.00 billion in the first nine months, increasing 50.30% year-on-year and accounting for 28.31% of total revenue, up 5.82 percentage points from the same period last year.
In Europe, revenue grew nearly 30% year-on-year in the first nine months. Cumulative deliveries exceeded 850 systems, with high-end imaging equipment deployed in more than half of EU member states. Supported by a regional business team of over 160 employees, the company continued to advance high-end imaging projects and strengthen local customer support. In North America, United Imaging Healthcare expanded relationships with integrated delivery networks and secured eligibility under framework agreements.
Asia-Pacific revenue increased by more than 100% year-on-year in Q1–Q3 2026, with continued progress in Singapore, Japan, South Korea, Australia and New Zealand. Multiple high-end MRI systems were installed within Singapore Health Services (SingHealth), while PET/CT installations continued to increase in Australia. Japan’s first uMI Panvivo PET/CT system was installed at Saitama Central Clinic.
In China, the company’s market share increased by 2.2 percentage points year-on-year in the first nine months, supported by its broad product portfolio and continued progress in high-end imaging, interventional systems and radiotherapy.
Continued regulatory progress and intellectual property development supported the company’s global expansion. As of September 30, 2026, 170 products had obtained approval from China’s National Medical Products Administration (NMPA), 84 had received CE certification and 79 had obtained U.S. FDA 510(k) clearance. These included 18 additional NMPA approvals, 14 CE certifications and 21 FDA clearances during the first nine months. Eight products had been recognized under China’s national innovative medical device program.
More than 40 AI-enabled medical devices had received FDA clearance, and the company had completed the development and deployment of intelligent technology platforms across all product lines. Cumulative patent applications exceeded 10,800, with invention patents accounting for more than 80%, while granted patents totaled over 5,700.
As of the end of the reporting period, United Imaging Healthcare’s products served more than 100 countries and regions, reaching over 17,000 medical and research institutions. Cumulative system deliveries exceeded 41,000, supported by a global network of more than 1,100 service engineers.
Looking ahead, the company will continue to strengthen local operations and service capabilities worldwide, expand access to advanced medical technologies and support sustainable growth through innovation.
